Transient Increase in Squamous Cell Carcinoma Antigen Expression in Cultured Cervical Carcinoma CaSki Cells in Response to Exposure to cis-Diamminedichloroplatinum

Tumor Biology

Volumn 24, Issue 5, 2003, Pages 219-227

  Tateiwa, Y ^a   Yoshida, S ^a   Miyahara, Y ^a   Hamana, S ^a   Motoyama, S ^a   Maruo, T ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; CaSki cells; cis Diamminedichloroplatinum; SCC Ag 1; SCC Ag 2; Uterine cervical carcinoma

Indexed keywords

BROXURIDINE; CISPLATIN; MESSENGER RNA; SQUAMOUS CELL CARCINOMA ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN 1; SQUAMOUS CELL CARCINOMA ANTIGEN 2; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL PROLIFERATION; CIRCULATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG EXPOSURE; DRUG INFUSION; DRUG RESPONSE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; INCUBATION TIME; MOLECULAR MECHANICS; NICK END LABELING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SOUTHERN BLOTTING; TIME; UTERINE CERVIX CARCINOMA;

EID: 1542343904     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076136     Document Type: Article

References (29)

1. Kato H, Torigoe T: Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977;41:1621-1628.
2. Kato H, Morioka H, Tsutsui H, Aramaki S, Torigoe T: Value of tumour-antigen (TA-4) of squamous cell carcinoma in predicting the extent of cervical cancer. Cancer 1982;50:1294-1296.
3. Maruo T, Shibata K, Kimura A, Hoshina A, Mochizuki M: Tumour-associated antigen, TA-4, in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix. Cancer 1985;59:302-308.
4. Suminami Y, Kishi F, Sekiguchi K, Kato H: Squamous cell carcinoma antigen is a new member of serine protease inhibitors. Biochem Biophys Res Commun 1991;181:51-58.
5. Kuwano A, Kondo I, Kishi F, Suminami Y, Kato H: Assignment of the squamous cell carcinoma antigen locus (SCC) to 18q21 by in situ hybridization. Genomics 1995;30:626.
6. Schneider SS, Schick C, Fish KE, Miller E, Pena JC, Treter SD, Hui SM, Silverman GA: A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci USA 1995;92:3147-3151.
7. Nawata S, Tsunaga N, Numa F, Tanaka T, Nakamura K, Kato H: Serine protease inhibitor activity of recombinant squamous cell carcinoma antigen towards chymotrypsin, as demonstrated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Electrophoresis 1995;16:1027-1030.
8. Schick C, Kamachi Y, Bartuski AJ, Cataltepe S, Schechter NM, Pemberton PA, Silverman GA: Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase. J Biol Chem 1997;17:1849-1855.
9. Schick C, Pemberton PA, Shi GP, Kamachi Y, Catalpete S, Bartuski AJ, Cornstein ER, Brömme D, Chapmann HA, Silverman GA: Cross-class inhibition of the cysteine proteinases cathepsin K, L, S by the serpin squamous cell carcinoma antigen 1: A kinetic analysis. Biochemistry 1998;37:5258-5266.
10. Weiner SA, Aristizabal S, Aiberts DS, Surwit EA, Deatherage-Deuser K: A phase II trial of mitomycin, vincristine, bleomycin and cisplatin (MOBP) as neoadjuvant therapy in high-risk cervical carcinoma. Gynecol Oncol 1988;30:1-6.
11. Gershenson DM, Morris M, Burke TW, Levenback C, Kavanagh JJ, Fromm GL, Silva EG, Warner D, Wharton JT: Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer. Gynecol Oncol 1995;58:349-355.
12. Sardi JE, Sananes C, Giaroli A, Bayo J, Rueda NG, Vighi S, Guardado N, Paniceres G, Snaidus L, Vico C: Results of prospective randomized trial with neoadjuvant chemotherapy in stage Ib, bulky, squamous carcinoma of the cervix. Gynecol Oncol 1993;49:156-165.
13. Fujiwaki R, Iida K, Ohnishi Y, Watanabe Y, Ryuuko K, Takahashi K, Miyazaki K: Intraarterial neoadjuvant chemotherapy following by radical surgery and radiotherapy for stage IIb cervical carcinoma. Anticancer Res 1997;17:3751-3756.
14. Panici PB, Scambia G, Greggi S, Ragusa G, Gallo A, Conte M, Battaglia F, Laurelli G, Rabitti C: Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival. Obstet Gynecol 1988;71:344-348.
15. Blumenreich MS, Woodcock TM, Jones M, Richman SP Gentile PS, Kubota TT, Allegra JC: Hi-dose cisplatin in patients with advanced malignancies. Cancer 1985;55:1118-1122.
16. Maruo T: Factors regulating SCC antigen expression in squamous cell carcinoma of the uterine cervix. Tumor Biol 1998;19:494-504.
17. Pattillo RA, Hussa RO, Story MT, Ruckert AC, Shalaby MR, Mattingly RF: Tumor antigen and human chorionic gonadotropin in CaSki cells: a new epidermoid cervical cancer cell line. Science 1977;196(4297):1456-1458.
18. Hamana S, Motoyama S, Takeuchi T, Ku Y, Yoshida S, Miyahara Y, Tateiwa Y, Maruo T: Super high-dose intraarterial cisplatin infusion under percutaneous pelvic perfusion with extracorporeal chemofiltration for advanced uterine cervical carcinoma. I. Analysis for pharmacokinetics, tumor response and toxicity of platinum. Am J Clin Oncol 2001;24:241-246.
19. Motoyama S, Takeuchi S, Hamana S, Ku Y, Miyahara Y, Tateiwa Y, Yoshida S, Maruo T: Super high-dose intraarterial cisplatin infusion under percutaneous pelvic perfusion with extracorporeal chemofiltration for advanced uterine cervical carcinoma. II. Its impact on clinical response and subsequent surgery. Am J Clin Oncol 2001;24:247-250.
20. Kato H, Nagaya T, Torigoe T: Heterogeneity of a tumor antigen TA-4 of squamous cell carcinoma in relation to its appearance in the circulation. Gann 1984;75:433-435.
21. Hamada K, Hanakawa Y, Hashimoto K, Iwamoto M, Kihana T, Hirose S, Nakamura M, Ito M: Gene expression of human squamous cell carcinoma antigen 1 and 2 in human cell lines. Oncol Rep 2001;8:347-354.
22. Kerr JFR, Wyllie AH, Currie AR: Apoptosis: Basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257.
23. Wyllie AH, Kerr JFR, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 1980;68:251-306.
24. Kaufmann SH: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note. Cancer Res 1989;49:5870-5878.
25. Meyn RE, Stephens LC, Hunter NR, Milas L: Induction of apoptosis in murine tumors by cyclophosphamide. Cancer Chemother Pharmacol 1994;33:410-414.
26. Meyn RE, Stephens LC, Hunter NR, Milas L: Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs 1995;6:443-450.
27. Searle J, Lawson TA, Abbott PJ, Harmon B, Kerr JF: An electron-microscope study of mode of cell death induced by cancer- chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Pathol 1975;116:129-138.
28. Suminami Y, Nagashima S, Murakami A, Nawata S, Gondo T, Hirakawa H, Numa F, Silverman GA, Kato H: Suppression of a squamous cell carcinoma (SCC)-related serpin, SCC antigen, inhibits tumor growth with increased intratumor infiltration of natural killer cells. Cancer Res 2001;61:1776-1780.
29. Murakami A, Suminami Y, Hirakawa H, Nawata S, Numa F, Kato H: Squamous cell carcinoma antigen suppresses radiation-induced cell death. Br J Cancer 2001;84:851-858.